{"id":40158,"date":"2021-03-12T07:39:55","date_gmt":"2021-03-12T07:39:55","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40158"},"modified":"2021-11-21T13:02:57","modified_gmt":"2021-11-21T13:02:57","slug":"dosing-for-once-weekly-oral-art-islatravir-plus-mk-8507-studies-due-to-start-in-2021","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40158","title":{"rendered":"CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021"},"content":{"rendered":"

\"\"<\/span>Simon Collins, HIV i-Base<\/strong><\/p>\n

CROI 2021 included several studies on a once-weekly oral combinations using islatravir and a new NNRTI MK-8501. [1]<\/span><\/strong><\/p>\n

A single 20 mg once-weekly dose of islatravir was shown to produce intracellular concentrations that is similar to steady-state using the 0.75 mg daily dose. After 14 days, islatravir levels were still five-fold above the inhibitory quotient for lamivudine resistant HIV, showing this would also have some flexibility it a single dose was later or missed. [1]<\/span><\/p>\n

The study modelling for dosing MK-8507 was based on real world simulations in combination with islatravir and assuming 80% adherence. The study reported that the three doses studies – 100 mg, 200 mg and 400 mg – should all provide >90% efficacy against common NNRTI mutations including K103N and Y181C.<\/p>\n

MK-8507 has a half-life of ~70 hours and mean viral load reductions of \u20131.5 log once week after a single dose were reported at Glasgow 2020. [2]<\/span><\/p>\n

An oral presentation at CROI 2021 also presented additional new information about MK-8507, including activity against early NNRTIs (K103N, Y181C and G190A) \u2013 with a resistance profile similar to doravirine. [3] <\/span><\/p>\n

Studies using islatravir plus MK-8507 in a dual once-weekly combination are planned to start later in 2021.<\/span><\/p>\n

References<\/p>\n

    \n
  1. Kandala B et al. Model-informed dose selection for islatravir\/MK-8507 oral once-weekly phase 2b study. <\/span>CROI 2021, 6\u201310 March 2021. Poster 376.
    \nhttps:\/\/www.croiconference.org\/abstract\/model-informed-dose-selection-for-islatravir-mk-8507-oral-once-weekly-phase-2b-study\/<\/a>
    \n<\/span><\/li>\n
  2. Single doses of MK-8507 reduce viral load by mean \u20131.5 log and support once-weekly dosing above 80 mg. HTB (14 October 2020).
    \n    https:\/\/i-base.info\/htb\/39085<\/span><\/a><\/li>\n
  3. Diamond T et al. <\/span>Resistance profile of MK-8507, a novel NNRTI suitable for weekly oral HIV treatment. CROI 2021, 6\u201310 March 2021. Oral abstract 129.
    \n    https:\/\/www.croiconference.org\/abstract\/resistance-profile-of-mk-8507-a-novel-nnrti-suitable-for-weekly-oral-hiv-treatment\/<\/a> (abstract and webcast)<\/li>\n<\/ol>\n

    This report was first posted on 9 March 2021.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base CROI 2021 included several studies on a once-weekly oral combinations using islatravir and a new NNRTI MK-8501. [1] A single 20 mg once-weekly dose of islatravir was shown to produce intracellular concentrations that is similar to …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[307],"class_list":["post-40158","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-croi-2021-virtual"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40158"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40158\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}